Literature DB >> 22290895

Antegrade selective cerebral perfusion and moderate hypothermia in aortic arch surgery: clinical outcomes in elderly patients.

Davide Pacini1, Luca Di Marco, Alessandro Leone, Roberto Di Bartolomeo, Gottfried Sodeck, Lars Englberger, Thierry Carrel, Martin Czerny.   

Abstract

OBJECTIVES: To evaluate the outcome in elderly patients (≥ 75 years) undergoing elective aortic arch surgery with the aid of selective antegrade cerebral perfusion (SACP) and moderate hypothermic circulatory arrest (HCA).
METHODS: A series of 95 patients ≥ 75 years (median age 77 years, median EuroSCORE 28) undergoing elective aortic arch surgery with SACP and moderate HCA were analysed with regard to clinical outcome. Risk factors for serious adverse events (mortality, neurological injury) were determined.
RESULTS: Sixty-three patients (66%) underwent ascending aorta and hemiarch replacement, whereas 32 patients (34%) underwent ascending aorta and total arch replacement. Isolated arch replacement was rare. Additionally, 27% of patients underwent aortic valve replacement and 26% underwent root replacement. In-hospital mortality was 7%. Permanent neurological deficits occurred in 5%, transient neurological deficits occurred in 2%. Median SACP time was 24 min. Univariate analysis revealed femoral cannulation site (OR: 3.4; CI: 1.25-9.22, P = 0.016) as well as HCA ≥ 40 min (OR: 4.21; CI: 1.83-12.58, P = 0.001) as predictors of serious adverse events (mortality, neurological injury).
CONCLUSIONS: Summarizing, elective aortic arch surgery in elderly patients using SACP and moderate HCA provides excellent results regarding mortality and postoperative neurological outcome. Prolonged HCA time and femoral cannulation were the only predictors of serious adverse events (mortality, neurological injury).

Entities:  

Mesh:

Year:  2012        PMID: 22290895     DOI: 10.1093/ejcts/ezr304

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

Review 1.  Neuroprotective Strategies in Repair and Replacement of the Aortic Arch.

Authors:  Frank Manetta; Clancy W Mullan; Michael A Catalano
Journal:  Int J Angiol       Date:  2018-05-27

2.  Antegrade cerebral perfusion at 25 °C for arch reconstruction in newborns and children preserves perioperative cerebral oxygenation and serum creatinine.

Authors:  Bhawna Gupta; Ali Dodge-Khatami; Juan Tucker; Mary B Taylor; Douglas Maposa; Miguel Urencio; Jorge D Salazar
Journal:  Transl Pediatr       Date:  2016-07

3.  Combination treatment of hypothermia and mesenchymal stromal cells amplifies neuroprotection in primary rat neurons exposed to hypoxic-ischemic-like injury in vitro: role of the opioid system.

Authors:  Yuji Kaneko; Naoki Tajiri; Tsung-Ping Su; Yun Wang; Cesar V Borlongan
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

4.  Usefulness of Deep Hypothermic Circulatory Arrest and Regional Cerebral Perfusion in Children.

Authors:  Zheng Guo; Ren-Jie Hu; De-Ming Zhu; Zhong-Qun Zhu; Hai-Bo Zhang; Wei Wang
Journal:  Ther Hypothermia Temp Manag       Date:  2013-09       Impact factor: 1.286

5.  Total arch replacement versus debranching thoracic endovascular aortic repair for aortic arch aneurysm: what indicates a high-risk patient for arch repair in octogenarians?

Authors:  Yoshimasa Seike; Hitoshi Matsuda; Tetsuya Fukuda; Yosuke Inoue; Atsushi Omura; Kyokun Uehara; Hiroaki Sasaki; Junjiro Kobayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-01-31

Review 6.  Outcomes of surgery for acute type A dissection in octogenarians versus non-octogenarians: a systematic review and meta analysis.

Authors:  Aditya Eranki; Michael Merakis; Michael L Williams; Campbell D Flynn; Claudia Villanueva; Ashley Wilson-Smith; Yangsin Lee; Ross Mejia
Journal:  J Cardiothorac Surg       Date:  2022-09-01       Impact factor: 1.522

7.  Long-term results after proximal thoracic aortic redo surgery.

Authors:  Martin Czerny; Ilan Barchichat; Katharina Meszaros; Gottfried H Sodeck; Alberto Weber; David Reineke; Lars Englberger; Florian Schönhoff; Alexander Kadner; Hansjörg Jenni; Jürg Schmidli; Thierry P Carrel
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.